ONCE Spark Therapeutics Inc.

+0.95  (+2%)
Previous Close 50.61
Open 50.58
Price To Book 3.54
Market Cap 1946241353
Shares 37,747,117
Volume 522,921
Short Ratio
Av. Daily Volume 521,132

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 3 trial to be initiated late 2018. Phase 1/2 data updated data at ASH 2018 noted stable factor VIII activity levels in lower dose cohorts but high dose cohort data not noted. Further data due mid-2019.
Hemophilia A
Phase 1/2 updated data released May 22, 2018 - 98% decrease in bleeding rate.
Hemophilia B
Phase 1/2 update YE 2018.
SPK-7001 (SPK-CHM)
PDUFA date January 12, 2018 under priority review. Advisory Committee Meeting October 12, 2017 voted 16-0 in favor of recommending approval. Approval announced December 19, 2017.
Luxturna (voretigene neparvovec)
Inherited retinal dystrophies
Phase 3 lead-in trial initiation announced July 16, 2018.
FIX Replacement therapy
Hemophilia B

Latest News

  1. Inside Spark's quest to set the standards for gene therapy payments
  2. Edited Transcript of ONCE earnings conference call or presentation 19-Feb-19 1:30pm GMT
  3. New Research Coverage Highlights General Electric, Redfin, Splunk, Spark Therapeutics, Innospec, and Hemispherx BioPharma — Consolidated Revenues, Company Growth, and Expectations for 2019
  4. Spark Therapeutics (ONCE) Q4 2018 Earnings Conference Call Transcript
  5. Sales of Philadelphia-born gene therapy product hit $27M during first year
  6. Spark Therapeutics Reports 2018 Financial Results and Recent Business Progress
  7. Spark Therapeutics, Inc. to Host Earnings Call
  8. Spark Therapeutics (ONCE) May Report Negative Earnings: Know the Trend Ahead of Q4 Release
  9. Spark Therapeutics to Host Conference Call on Tuesday, Feb. 19 at 8:30 a.m. ET to Discuss 2018 Results and Recent Business Highlights
  10. This Gene Therapy Stock Could Soon Hit The Auction Block — Here's Why
  11. See what the IHS Markit Score report has to say about Spark Therapeutics Inc.
  12. Gene Therapy: Novartis Under The Microscope With Novel Treatment
  13. Novartis (NVS) Q4 Earnings Miss Estimates, Revenues Up Y/Y
  14. Spark Therapeutics Announces Presentation of Preclinical Data in Pompe Disease and CLN2 Disease at 15th Annual WORLDSymposium™
  15. Calculating The Intrinsic Value Of Spark Therapeutics, Inc. (NASDAQ:ONCE)
  16. Here's What Pushed bluebird bio Stock Down 44.3% in 2018
  17. Edited Transcript of ONCE earnings conference call or presentation 6-Nov-18 1:30pm GMT